Literature DB >> 18089713

Cell type-- dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines.

Jenny Fink1, Karl Sanders, Alexandra Rippl, Sylvia Finkernagel, Thomas L Beckers, Mathias Schmidt.   

Abstract

Multiple critical roles within mitosis have been assigned to Polo-like kinase 1 (Plk1), making it an attractive candidate for mitotic targeting of cancer cells. Plk1 contains two domains amenable for targeted interference: a kinase domain responsible for the enzymatic function and a polo box domain necessary for substrate recognition and subcellular localization. Here, we compare two approaches for targeted interference with Plk1 function, either by a Plk1 small-molecule enzyme inhibitor or by inducible overexpression of the polo box in human cancer cell lines. Inducible expression of the Plk1 polo box resulted in growth inhibition of RKOp27 human colon adenocarcinoma cells without obvious signs of mitotic abnormalities. A Plk1 kinase inhibitor in the same cell line arrested cells in mitosis with subsequent onset of apoptosis. Similarly, PC-3 human prostate cancer cells were growth inhibited on expression of the polo box. Prolonged expression of the polo box in these cells resulted in the occurrence of binucleated or multinucleated cells. In contrast, U2OS human osteosarcoma cells responded to overexpression of the polo box with a massive mitotic accumulation coinciding with the onset of apoptosis. Comparison of spindle formation revealed very similar mitotic abnormalities in polo box-overexpressing U2OS cells compared with U2OS cells treated with the Plk1 kinase inhibitor. We conclude that interference with polo box function and inhibition of Plk1 kinase activity can exert very similar phenotypic effects in certain cell lines but highly contrasting effects in others. This may point to subtle differences in the molecular machinery of mitosis regulation in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18089713     DOI: 10.1158/1535-7163.MCT-07-0048

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  5 in total

1.  RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer.

Authors:  Shaguna Seth; Yoshiyuki Matsui; Kathy Fosnaugh; Yan Liu; Narendra Vaish; Roger Adami; Pierrot Harvie; Rachel Johns; Gregory Severson; Tod Brown; Akihide Takagi; Susan Bell; Yan Chen; Feng Chen; Tianying Zhu; Renata Fam; Iwona Maciagiewicz; Erin Kwang; Michael McCutcheon; Ken Farber; Patrick Charmley; Michael E Houston; Alan So; Michael V Templin; Barry Polisky
Journal:  Mol Ther       Date:  2011-03-01       Impact factor: 11.454

2.  Plk5, a polo box domain-only protein with specific roles in neuron differentiation and glioblastoma suppression.

Authors:  Guillermo de Cárcer; Beatriz Escobar; Alonso M Higuero; Laura García; Alejandra Ansón; Gema Pérez; Manuela Mollejo; Gerard Manning; Bárbara Meléndez; José Abad-Rodríguez; Marcos Malumbres
Journal:  Mol Cell Biol       Date:  2011-01-18       Impact factor: 4.272

3.  Targeting sonic hedgehog-associated medulloblastoma through inhibition of Aurora and Polo-like kinases.

Authors:  Shirley L Markant; Lourdes Adriana Esparza; Jesse Sun; Kelly L Barton; Lisa M McCoig; Gerald A Grant; John R Crawford; Michael L Levy; Paul A Northcott; David Shih; Marc Remke; Michael D Taylor; Robert J Wechsler-Reya
Journal:  Cancer Res       Date:  2013-09-25       Impact factor: 12.701

4.  Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.

Authors:  Valeria Sero; Elisa Tavanti; Serena Vella; Claudia Maria Hattinger; Marilù Fanelli; Francesca Michelacci; Rogier Versteeg; Barbara Valsasina; Beth Gudeman; Piero Picci; Massimo Serra
Journal:  Invest New Drugs       Date:  2014-09-07       Impact factor: 3.850

5.  Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells.

Authors:  Travis L Schmit; Weixiong Zhong; Vijayasaradhi Setaluri; Vladimir S Spiegelman; Nihal Ahmad
Journal:  J Invest Dermatol       Date:  2009-06-25       Impact factor: 8.551

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.